BerGenBio to Present at Digital Novel Coronavirus Investment Forum
BERGEN, Norway, July 7, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs Associates Digital Novel Coronavirus Investment Forum on 8-9 July 2020.
- BERGEN, Norway, July 7, 2020 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that Dr. Akil Jackson, Medical Director at BerGenBio, will be participating at the Sachs Associates Digital Novel Coronavirus Investment Forum on 8-9 July 2020.
- Dr. Jackson will also deliver a presentation on BerGenBio at 11:35am CEST on 9 July.
- AXL kinase is a cell membrane receptor and an essential mediator of the biological mechanisms underlying life-threatening diseases.
- In cancer, AXL suppresses the body's immune response to tumours and drives cancer treatment failure across many indications.